Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial

INTRODUCTION: Here we report the glycemic efficacy and safety of ertugliflozin in patients in the VERTIS CV cardiovascular outcome trial with chronic kidney disease (CKD) stage 3. RESEARCH DESIGN AND METHODS: Prespecified and post-hoc analyses were performed in patients with an estimated glomerular...

Descripción completa

Detalles Bibliográficos
Autores principales: Dagogo-Jack, Samuel, Pratley, Richard E, Cherney, David Z I, McGuire, Darren K, Cosentino, Francesco, Shih, Weichung J, Liu, Jie, Frederich, Robert, Mancuso, James P, Raji, Annaswamy, Gantz, Ira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Cardiovascular and Metabolic Risk
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8499340/
https://www.ncbi.nlm.nih.gov/pubmed/34620621
http://dx.doi.org/10.1136/bmjdrc-2021-002484

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8499340/
https://www.ncbi.nlm.nih.gov/pubmed/34620621
http://dx.doi.org/10.1136/bmjdrc-2021-002484

Ejemplares similares